GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ziccum AB (OSTO:ZICC) » Definitions » Debt-to-Revenue

Ziccum AB (OSTO:ZICC) Debt-to-Revenue : 0.06 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Ziccum AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Ziccum AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.57 Mil. Ziccum AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.14 Mil. Ziccum AB's annualized Revenue for the quarter that ended in Mar. 2024 was kr11.55 Mil. Ziccum AB's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.06.


Ziccum AB Debt-to-Revenue Historical Data

The historical data trend for Ziccum AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ziccum AB Debt-to-Revenue Chart

Ziccum AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial N/A N/A N/A N/A 0.23

Ziccum AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 0.25 0.20 0.23 0.06

Competitive Comparison of Ziccum AB's Debt-to-Revenue

For the Biotechnology subindustry, Ziccum AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ziccum AB's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ziccum AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ziccum AB's Debt-to-Revenue falls into.



Ziccum AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Ziccum AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.571 + 0.286) / 3.747
=0.23

Ziccum AB's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.571 + 0.143) / 11.552
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Ziccum AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ziccum AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ziccum AB (OSTO:ZICC) Business Description

Traded in Other Exchanges
Address
Scheelevagen 15, LUND, SWE, 223 70
Ziccum AB develops dry powder preparations of biological pharmaceuticals. It develops and commercializes the patented spray drying technology known as LaminarPace.

Ziccum AB (OSTO:ZICC) Headlines

No Headlines